Loflucarban

Loflucarban

SCHEMBL149841

Fc1ccc(NC(=S)Nc2cc(Cl)cc(Cl)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 1.00
MEN1 O00255 5/20 0.73
KMT2A Q03164 5/20 0.73
ALDH1A1 P00352 2/20 0.73
MAOA P21397 2/20 0.73
MAPK1 P28482 2/20 0.63
GAA P10253 2/20 0.61
MAPT P10636 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
LMNA P02545 1/20 0.59
HTT P42858 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
IDO1 P14902 2/20 0.56
POLB P06746 1/20 0.56
NOX1 Q9Y5S8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16566455 0.84 MAOB (1.00) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL10099725 0.84 GAA (0.83) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL15484146 0.84 IDO1 (0.75) MAOBMEN1KMT2AALDH1A1MAPT
SCHEMBL6815632 0.81 MAOB (0.69) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL4349666 0.80 MAOB (0.66) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL6815207 0.79 MAOB (0.65) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL4348031 0.78 MAOB (0.64) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL14433806 0.77 MAOB (0.63) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL10710275 0.76 NOX1 (0.85) MAOBMEN1KMT2AALDH1A1MAOA
SCHEMBL18031169 0.76 GAA (1.00) MAOBMEN1KMT2AALDH1A1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099557-A1 ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) 2025-03-27 US claimed
EP-4374848-A1 ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION Shanghai Bao Pharmaceuticals Co., Ltd. (CN) 2024-05-29 EP claimed
CN-116801720-A Novel agrochemical compositions comprising 3-substituted benzamidine compounds and uses thereof 皮埃企业有限公司 2023-09-22 CN claimed
CN-105492004-A Method of treating topical microbial infections LUODA PHARMA PTY LTD 2016-04-13 CN claimed
CN-105492005-A Methods of treating microbial infections including mastitis LUODA PHARMA PTY LTD 2016-04-13 CN claimed
US-20160000748-A1 METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS Luoda Pharma Limited (IE) 2016-01-07 US claimed
US-20150366797-A1 METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS Luoda Pharma Limited (IE) 2015-12-24 US claimed
EP-2953623-A1 METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS Luoda Pharma Pty Ltd (AU) 2015-12-16 EP claimed
EP-2953624-A1 METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS Luoda Pharma Pty Ltd (AU) 2015-12-16 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20030007949-A1 Adhesive treatment for tinea corporis CLOSURE MEDICAL CORPORATION (US) 2003-01-09 US claimed
US-20030007948-A1 Adhesive treatment for skin yeast infections CLOSURE MEDICAL CORPORATION (US) 2003-01-09 US claimed
EP-1231948-A1 A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION Ever Power Holding Inc. (VG) 2002-08-21 EP claimed
WO-2001037890-A1 A PROPELLANT FREE SPRAY-ON SKIN PATCH COMPOSITION FOR IMPROVING WOUND HEALING AND FOR DRUG ADMINISTRATION EVER POWER HOLDING INC (VG) 2001-05-31 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5811078-A IN A SOLVENT MIXTURE WITH ETHYL OR ISOPROPYL ALCOHOL AND WATER ADOLOR CORPORATION (US) 1998-09-22 US claimed
EP-0852494-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-15 EP claimed
WO-1997009973-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-03-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000748-A1 METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS TSLP, CCL11, IL17A MAOB 3073/4885MEN1 3888/4885KMT2A 3745/4885
US-20150366797-A1 METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS LCT, TSLP, MLEC MAOB 3927/4885MEN1 3344/4885KMT2A 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.